Nemes Rush Group’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.12M Buy
17,875
+613
+4% +$49K 0.11% 99
2025
Q4
$1.65M Sell
17,262
-2,841
-14% -$279K 0.15% 84
2025
Q3
$1.96M Buy
20,103
+77
+0.4% +$7.97K 0.19% 77
2025
Q2
$2.15M Buy
20,026
+19,391
+3,054% +$1.96M 0.23% 75
2025
Q1
$64.1K Hold
635
0.01% 288
2024
Q4
$56.7K Buy
635
+481
+312% +$42.3K 0.01% 291
2024
Q3
$10.5K Hold
154
﹤0.01% 395
2024
Q2
$11.9K Sell
154
-613
-80% -$44.9K ﹤0.01% 393
2024
Q1
$52.5K Hold
767
0.01% 267
2023
Q4
$44.3K Hold
767
0.01% 270
2023
Q3
$40.5K Buy
767
+154
+25% +$8.08K 0.01% 274
2023
Q2
$33.2K Buy
+613
New +$32K 0.01% 310

Other funds holding BSX

Nemes Rush Group's BSX Position: Q1 2026 in Review

Nemes Rush Group increased its Boston Scientific (BSX) stake by 3.6% in Q1 2026, buying an estimated $49K and bringing the position to 17,875 shares worth $1.12M. The position accounts for 0.11% of the portfolio, ranked #99.

Nemes Rush Group first reported a position in BSX in Q2 2023 and has held it in 12 quarters since. The position peaked at $2.15M in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Nemes Rush Group held 17,875 shares of Boston Scientific worth $1.12M as of Q1 2026.
  • Nemes Rush Group bought 613 Boston Scientific shares in Q1 2026, an estimated $49K.
  • Boston Scientific made up 0.11% of Nemes Rush Group's portfolio in Q1 2026, its #99 holding.
  • Nemes Rush Group first reported a position in Boston Scientific in Q2 2023 and has held it in 12 quarters since.
  • Nemes Rush Group's Boston Scientific position peaked at $2.15M in Q2 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.